Benchmarking heart failure care: the ANZACS-QI Heart Failure Registry Pilot implementation and results (ANZACS-QI 86)

aims: Heart failure is a major healthcare problem in Aotearoa New Zealand. As therapies advance and become increasingly complex it is essential that we systematically characterise phenotype and monitor adherence to relevant guidelines to drive quality improvement. Here we report the results of the ANZACS-QI Heart Failure Registry Pilot, implemented in Northern Region hospitals. methods: Age-stratified random sampling was used to identify a representative cohort of patients hospitalised with heart failure (2022 and 2023) using national administrative datasets. The electronic clinical records were reviewed and data entered into the web-based registry. Pre-specified outcomes that were analysed included rates of left ventricular assessment (left ventricular ejection fraction [LVEF]) and prescription of guideline-directed medical therapy (GDMT). results: The cohort comprised 328 patients and registry form completion rates were high (98%). LVEF assessment rates within 2 years of the index hospital discharge were 81%. Of those with heart failure with reduced ejection fraction that survived until discharge (n=137), only 13 (9%) met the composite medication indicator of being prescribed (or with documented contraindication/intolerance) all four GDMT classes. This was largely driven by 92 (67%) being ineligible for subsidy for sodium glucose co-transporter-2 inhibitors; however, prescription rates of the other GDMT classes were suboptimal. conclusions: Our study highlights that there is a considerable gap between guideline recommendations and real-world practice. Following pilot completion, performance indicators have been established and the registry has expanded with the goal for it to become national. The successful implementation of the registry is an important step in quality improvement for patients hospitalised with heart failure.

Authors

Publication Details

Journal
New Zealand Medical Journal
Published
2026-11-20
DOI
https://doi.org/10.26635/6965.7408
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Benchmarking heart failure care: the ANZACS-QI Heart Failure Registry Pilot implementation and results (ANZACS-QI 86)

Vanessa Selak, Mary Morgan, Mayanna Lund, Corina Grey et al.
3 links
New Zealand Medical Journal
Heart Failure Treatment and Management
article

Benchmarking heart failure care: the ANZACS-QI Heart Failure Registry Pilot implementation and results (ANZACS-QI 86)

Vanessa Selak, Mary Morgan, Mayanna Lund, Corina Grey, Andy McLachlan, Aleisha Easton, Robert Doughty, Susan Wells, Daniel Chan, Wil Harrison, Andrew Kerr, Sarah Adkin, Matire Harwood, Katrina Poppe, Ursula Balzat, Heather Brannigan
article en

Abstract

aims: Heart failure is a major healthcare problem in Aotearoa New Zealand. As therapies advance and become increasingly complex it is essential that we systematically characterise phenotype and monitor adherence to relevant guidelines to drive quality improvement. Here we report the results of the ANZACS-QI Heart Failure Registry Pilot, implemented in Northern Region hospitals. methods: Age-stratified random sampling was used to identify a representative cohort of patients hospitalised with heart failure (2022 and 2023) using national administrative datasets. The electronic clinical records were reviewed and data entered into the web-based registry. Pre-specified outcomes that were analysed included rates of left ventricular assessment (left ventricular ejection fraction [LVEF]) and prescription of guideline-directed medical therapy (GDMT). results: The cohort comprised 328 patients and registry form completion rates were high (98%). LVEF assessment rates within 2 years of the index hospital discharge were 81%. Of those with heart failure with reduced ejection fraction that survived until discharge (n=137), only 13 (9%) met the composite medication indicator of being prescribed (or with documented contraindication/intolerance) all four GDMT classes. This was largely driven by 92 (67%) being ineligible for subsidy for sodium glucose co-transporter-2 inhibitors; however, prescription rates of the other GDMT classes were suboptimal. conclusions: Our study highlights that there is a considerable gap between guideline recommendations and real-world practice. Following pilot completion, performance indicators have been established and the registry has expanded with the goal for it to become national. The successful implementation of the registry is an important step in quality improvement for patients hospitalised with heart failure.

New Zealand Medical JournalVol. 139(1646)
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon